2.12

0.47% 0.01

After Hours: 2.11 -0.01 -0.47%

Therapeuticsmd Inc (TXMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Therapeuticsmd Inc stock is traded at $2.12, with a volume of 13,391. It is up +0.47% in the last 24 hours and up +0.47% over the past month. TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.

Previous Close:

$2.11

Open:

$2.1499

24h Volume:

13,391

Relative Volume:

0.63

Market Cap:

$24.54M

Revenue:

$3.02M

Net Income/Loss:

$-653.00K

P/E Ratio:

-43.00

EPS:

-0.0493

Net Cash Flow:

$2.42M

1W Performance:

+6.00%

1M Performance:

+0.47%

6M Performance:

+19.10%

1Y Performance:

+46.21%

1-Day Range:

$2.0404

$2.15

1-Week Range:

$2.02

$2.15

52-Week Range:

$0.9811

$2.95

Therapeuticsmd Inc Stock (TXMD) Company Profile

Name

Therapeuticsmd Inc

Sector

Healthcare (1108)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

561-961-1900

Address

951 YAMATO ROAD, SUITE 220, BOCA RATON, FL

Employee

Twitter

@TherapeuticsMD

Next Earnings Date

2026-05-12

Latest SEC Filings

TXMD's Discussions on Twitter

Compare TXMD vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TXMD Therapeuticsmd Inc	2.12	24.42M	3.02M	-653.00K	2.42M	-0.0493
TAK Takeda Pharmaceutical Co Adr	16.25	52.07B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.29	41.28B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.07	39.78B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	81.32	33.57B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	568.43	24.02B	3.17B	1.29B	1.01B	27.09

Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-07-20	Downgrade	Jefferies	Hold → Underperform
May-19-20	Downgrade	JP Morgan	Overweight → Neutral
Dec-02-19	Initiated	Guggenheim	Buy
Oct-17-19	Initiated	H.C. Wainwright	Buy
Apr-30-19	Resumed	Noble Capital Markets	Outperform
Jun-15-18	Initiated	JP Morgan	Overweight
Sep-08-17	Initiated	Morgan Stanley	Equal-Weight
Jul-11-17	Upgrade	Oppenheimer	Perform → Outperform
May-09-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-22-16	Resumed	Jefferies	Buy
Nov-22-16	Initiated	Oppenheimer	Outperform
Nov-07-16	Resumed	Guggenheim	Buy
Apr-04-16	Initiated	Goldman	Buy
Dec-08-15	Reiterated	Jefferies	Buy
Dec-08-15	Reiterated	Stifel	Buy
Sep-21-15	Reiterated	Jefferies	Buy
Jun-09-15	Initiated	Guggenheim	Buy
Jul-08-14	Initiated	FBR Capital	Outperform
Apr-17-14	Reiterated	Noble Financial	Buy
Jan-28-14	Reiterated	Noble Financial	Buy

View All

Therapeuticsmd Inc Stock (TXMD) Latest News

May 22, 2026

TherapeuticsMD (TXMD) Edges Higher as Support Holds Near $2.01Post-Earnings Moves - Newser

May 22, 2026

May 21, 2026

TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch

May 21, 2026

May 17, 2026

What TherapeuticsMD TXMD flagged as biggest challenges ahead Q3 2023 EPS Misses ViewsRetail Trader Ideas - newser.com

May 17, 2026

May 14, 2026

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch

May 14, 2026

May 13, 2026

TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives - TipRanks

May 12, 2026

TherapeuticsMD: Q1 Earnings Snapshot - marketscreener.com

May 12, 2026

TherapeuticsMD swings to Q1 net income as license revenue rises - TradingView

May 12, 2026

TherapeuticsMD (TXMD) details Q1 2026 results and strategic review - Stock Titan

May 12, 2026

May 11, 2026

TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch

May 11, 2026

May 10, 2026

What TherapeuticsMD (TXMD) flagged as biggest challenges ahead | Q3 2023: EPS Misses ViewsStock Trading Network - Newser

May 10, 2026

May 08, 2026

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch

May 08, 2026

May 06, 2026

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

May 06, 2026

May 01, 2026

TXMD Stock Price, Quote & Chart | THERAPEUTICSMD INC (NASDAQ:TXMD) - ChartMill

May 01, 2026

Apr 24, 2026

TXMD Should I Buy - Intellectia AI

Apr 24, 2026

Apr 23, 2026

TXMD (TherapeuticsMD Inc.) posts far wider Q3 2023 loss than expected, with shares dipping 0.48% in today’s trading.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 22, 2026

TXMD (TherapeuticsMD Inc.) Q3 2023 EPS misses consensus estimates by wide margin as shares dip 0.48 percent in today's trading.Trending Stock Ideas - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Apr 21, 2026

TXMD (TherapeuticsMD) shares gain 5.8 percent despite wider than expected Q3 2023 per share loss.Earnings Revision Report - Newser

Apr 21, 2026

Apr 11, 2026

Form 10-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]: [Amend] - ADVFN

Apr 11, 2026

Apr 09, 2026

Total debt per share of TherapeuticsMD, Inc. – MUN:29TA - TradingView — Track All Markets

Apr 09, 2026

Apr 08, 2026

TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch

Apr 08, 2026

Apr 07, 2026

TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Apr 07, 2026

Apr 06, 2026

[SCHEDULE 13G] TherapeuticsMD, Inc. Passive Investment Disclosure (>5%) - Stock Titan

Apr 06, 2026

Profit Recap: Is TherapeuticsMD Inc stock a buy or sell2026 Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn

Apr 06, 2026

Apr 02, 2026